0.00Open0.05Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV-65.91%PremiumSep 20, 2024Expiry Date4.98Intrinsic Value100Multiplier59DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma149.63Leverage Ratio--Theta--Rho--Eff Leverage--Vega
TrytosaveabitOP : Pieris Pharmaceuticals- Servier's Decision to Terminate Agreements Was Based on a Potential Safety Concern in S095012 Phase 1 Clinical Studies